Audentes Therapeutics Inc (BOLD):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Audentes Therapeutics Inc (BOLD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8283
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:62
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Audentes Therapeutics Inc (Audentes) is a biotechnology company that focuses on the development and commercialization of gene therapy products for serious and life-threatening rare diseases. The company’s pipeline products include AT132, intended for the treatment of X-linked myotubular myopathy; AT982, for the treatment of Pompe disease; AT342, for the treatment of crigler-najjar syndrome; and AT307, for the treatment of CASQ2-related catecholaminergic polymorphic ventricular tachycardia. Audentes offers viral vectors for gene therapy most frequently and track record off adeno-associated virus vector (AAV) in non-pathogenic product, among others. The company has collaboration with various patient, research and medical communities to advance its product candidates. Audentes is headquartered in San Francisco, California, the US.

Audentes Therapeutics Inc (BOLD) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Audentes Therapeutics Raises USD65 Million in Series C Financing Round 12
Audentes Therapeutics Raises USD42.5 Million in Series B Financing 15
Cardiogen Sciences Secures USD0.52 Million in Venture Funding 17
Audentes Therapeutics Raises US$30 Million In Series A Financing 18
Audentes Therapeutics Raises Funds through Seed Financing 20
Partnerships 21
Audentes Therapeutics Amends Co-Development with University of Pennsylvania 21
Audentes Therapeutics Enters Into Co-Development Agreement With Genethon For AT001 22
Licensing Agreements 23
Audentes Therapeutics Enters Into Licensing Agreement With RegenxBio 23
Audentes Therapeutics Enters into Licensing Agreement with RegenxBio for CPVT 24
Audentes Therapeutics Amends its Licensing Agreement with University of Florida Research Foundation 26
Cardiogen Sciences Enters into Licensing Agreement with Fondazione Salvatore Maugeri 27
Audentes Therapeutics Enters Into Licensing Agreement with ReGenX Biosciences 28
Equity Offering 29
Audentes Therapeutics Prices Public Offering of Shares for USD150.8 Million 29
Audentes Therapeutics Raises USD231 Million in Public Offering of Shares 31
Audentes Therapeutics to Raise up to USD75 Million in Public Offering of Shares 33
Audentes Therapeutics Raises USD86.3 Million in Public Offering of Shares 34
Audentes Therapeutics Raises USD75 Million in IPO 36
Acquisition 37
Audentes Therapeutics Acquires Cardiogen Sciences 37
Audentes Therapeutics Inc – Key Competitors 38
Audentes Therapeutics Inc – Key Employees 39
Audentes Therapeutics Inc – Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40
Recent Developments 41
Financial Announcements 41
Aug 07, 2018: Audentes Therapeutics Reports Second Quarter 2018 Financial Results 41
May 09, 2018: Audentes Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update 43
Mar 08, 2018: Audentes Therapeutics Announces Fourth Quarter 2017 And Full Year Financial Results 45
Nov 14, 2017: Audentes Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update 46
Aug 10, 2017: Audentes Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update 47
May 11, 2017: Audentes Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update 49
Mar 09, 2017: Audentes Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 51
Jan 09, 2017: Audentes Therapeutics Provides Full Year 2017 Strategic Outlook and Financial Guidance 54
Corporate Communications 56
Oct 03, 2018: Audentes Therapeutics announces co-founder and chief executive Officer Matthew R. Patterson appointed chairman of the alliance for regenerative medicine 56
May 08, 2018: Audentes Therapeutics Announces the Promotion of Natalie Holles to President and Chief Operating Officer 57
Dec 13, 2017: Audentes Therapeutics Appoints Mark A. Goldberg, M.D. to its Board of Directors 58
Jun 13, 2017: Audentes Therapeutics Appoints Jennifer Jarrett to Board of Directors 59
May 08, 2017: Audentes Therapeutics Announces Appointment of John T. Gray, Ph.D. to Senior Vice President and Chief Scientific Officer 60
Product News 61
04/30/2018: Audentes Therapeutics Announces Presentation of Data at the 21st Annual Meeting of the American Society of Gene and Cell Therapy 61
Appendix 62
Methodology 62
About GlobalData 62
Contact Us 62
Disclaimer 62

List of Tables
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Audentes Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Audentes Therapeutics Raises USD65 Million in Series C Financing Round 12
Audentes Therapeutics Raises USD42.5 Million in Series B Financing 15
Cardiogen Sciences Secures USD0.52 Million in Venture Funding 17
Audentes Therapeutics Raises US$30 Million In Series A Financing 18
Audentes Therapeutics Raises Funds through Seed Financing 20
Audentes Therapeutics Amends Co-Development with University of Pennsylvania 21
Audentes Therapeutics Enters Into Co-Development Agreement With Genethon For AT001 22
Audentes Therapeutics Enters Into Licensing Agreement With RegenxBio 23
Audentes Therapeutics Enters into Licensing Agreement with RegenxBio for CPVT 24
Audentes Therapeutics Amends its Licensing Agreement with University of Florida Research Foundation 26
Cardiogen Sciences Enters into Licensing Agreement with Fondazione Salvatore Maugeri 27
Audentes Therapeutics Enters Into Licensing Agreement with ReGenX Biosciences 28
Audentes Therapeutics Prices Public Offering of Shares for USD150.8 Million 29
Audentes Therapeutics Raises USD231 Million in Public Offering of Shares 31
Audentes Therapeutics to Raise up to USD75 Million in Public Offering of Shares 33
Audentes Therapeutics Raises USD86.3 Million in Public Offering of Shares 34
Audentes Therapeutics Raises USD75 Million in IPO 36
Audentes Therapeutics Acquires Cardiogen Sciences 37
Audentes Therapeutics Inc, Key Competitors 38
Audentes Therapeutics Inc, Key Employees 39
Audentes Therapeutics Inc, Subsidiaries 40

List of Figures
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Audentes Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Audentes Therapeutics Inc (BOLD):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Checkpoint Systems, Inc.:企業の戦略・SWOT・財務情報
    Checkpoint Systems, Inc. - Strategy, SWOT and Corporate Finance Report Summary Checkpoint Systems, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Anglo American Plc:企業の戦略・SWOT・財務情報
    Anglo American Plc - Strategy, SWOT and Corporate Finance Report Summary Anglo American Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Thames Water Utilities Ltd:企業の戦略・SWOT・財務情報
    Thames Water Utilities Ltd - Strategy, SWOT and Corporate Finance Report Summary Thames Water Utilities Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Ridley USA, Inc.:企業の戦略的SWOT分析
    Ridley USA, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • numares AG:企業の製品パイプライン分析2018
    Summary Numares AG (Numares), formerly Numares GmbH, is a developer and marketer of products for life science research and clinical diagnostics. The company’s AXINON lipoFIT, a test system used for lipoprotein profiling, while insightLP provides insights into lipid related research using lipoprotein …
  • Organogenesis Inc:医療機器:M&Aディール及び事業提携情報
    Summary Organogenesis Inc (Organogenesis) is a regenerative medicine company that operates in the areas of bioactive wound healing and soft tissue regeneration. The company’s products include apligraf and dermagraft. Its dermagraft is used for the treatment of full-thickness diabetic foot ulcers. Or …
  • Royal College of Surgeons Ireland:製薬・医療:M&Aディール及び事業提携情報
    Summary Royal College of Surgeons Ireland (RCSI) is an educational institution that offers medical education and training in healthcare professions at undergraduate and postgraduate levels. The institute provides undergraduate courses in nursing, postgraduate research, leadership courses, and surgic …
  • CMC Biologics AS:製薬・医療:M&Aディール及び事業提携情報
    Summary CMC Biologics A/S (CMC Biologics), formerly CMC Biopharmaceuticals A/S, a subsidiary of Asahi Glass Co., Ltd., is a contract process development and manufacturer of biopharmaceuticals. The company's service portfolio encompasses process development, cGMP manufacturing, and quality and regula …
  • Lutronic Corp (085370):企業の財務・戦略的SWOT分析
    Lutronic Corp (085370) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • EXOR SpA:企業のM&A・事業提携・投資動向
    EXOR SpA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's EXOR SpA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital …
  • Micron Technology Inc:企業の戦略・SWOT・財務情報
    Micron Technology Inc - Strategy, SWOT and Corporate Finance Report Summary Micron Technology Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • U.S. Bancorp:企業のM&A・事業提携・投資動向
    U.S. Bancorp - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's U.S. Bancorp Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Best Buy Co, Inc.:企業の戦略・SWOT・財務情報
    Best Buy Co, Inc. - Strategy, SWOT and Corporate Finance Report Summary Best Buy Co, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • J D Wetherspoon plc:企業の戦略・SWOT・財務情報
    J D Wetherspoon plc - Strategy, SWOT and Corporate Finance Report Summary J D Wetherspoon plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Wood Group Mustang Inc-石油・ガス分野:企業M&A・提携分析
    Summary Wood Group Mustang, Inc. (Wood Group Mustang), a subsidiary of John Wood Group PLC is an engineering management company. It provides engineering, procurement, and construction management (EPC) services to clients across diverse end markets. The company’s service portfolio comprises design an …
  • First Bancorp. (FBP):企業の財務・戦略的SWOT分析
    First Bancorp. (FBP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Exelon Corporation:企業の戦略・SWOT・財務情報
    Exelon Corporation - Strategy, SWOT and Corporate Finance Report Summary Exelon Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Kirby Corp (KEX):企業の財務・戦略的SWOT分析
    Kirby Corp (KEX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Omniox Inc-製薬・医療分野:企業M&A・提携分析
    Summary Omniox Inc (Omniox) is a biotechnology company that develops new medicines for hypoxic diseases. The company's H-NOX products are tailored for the treatment of hypoxic cancers, which include giloblastoma, metastatic brain cancer, head-and-neck cancer, pancreatic cancer, lung cancer, and pros …
  • GC Pharma (006280):企業の財務・戦略的SWOT分析
    GC Pharma (006280) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆